The cysteine-less peptidic anticoagulants madanin-1 and madanin-2 from the bush tick Haemaphysalis longicornis are the founding members of the MEROPS inhibitor family I53. It has been previously suggested that madanins exert their functional activity by competing with physiological substrates for binding to the positively charged exosite I (fibrinogenbinding exosite) of a-thrombin. We hereby demonstrate that competitive inhibition of a-thrombin by madanin-1 or madanin-2 involves binding to the enzyme's active site. Moreover, the blood coagulation factors IIa and Xa are shown to hydrolyze both inhibitors at different, although partially overlapping cleavage sites. Finally, the three-dimensional structure of the complex formed between human a-thrombin and a proteolytic fragment of madanin-1, determined by X-ray crystallography, elucidates the molecular details of madanin-1 recognition and processing by the proteinase. Taken together, the current findings establish the mechanism of action of madanins, natural anticoagulants that behave as cleavable competitive inhibitors of thrombin.
Introduction
Ticks are parasitic arthropods that feed on mammalian blood, a task that is assisted by the action of a range of antihemostatic compounds present in their saliva, eggs and hemolymph [1] . In addition to preventing host blood coagulation, these compounds have been postulated to play a role in tick hemolymph coagulation itself [2] .
The bush tick Haemaphysalis longicornis belongs to the Ixodidae or hard-tick family. This family represents 80% of the world's tick fauna and its global economic importance is mostly related to its impact on livestock [3] . Adult female hard ticks feed only once (dying after oviposition) but for a prolonged period of time [4] . This feeding habit allows for both delivery and uptake of bloodborne parasites, thus explaining the role of ticks as important vectors of livestock-affecting diseases [5] . The genus Haemaphysalis is mostly prevalent in tropical areas and is characterized by small size inortate ticks with short mouthparts (brevirostrate) [6] . Of particular concern is the impact of H. longicornis in the livestock industry in Japan and other East Asian countries, mainly due to the transmission of the anemia-causing intraerythrocytic protozoa, Theileria sergenti and Th. buffeli.
Two isoforms of a thrombin inhibitor, madanin-1 and madanin-2, sharing 79% amino acid sequence identity, were identified in salivary gland cDNA libraries of H. longicornis ticks [7, 8] . Given the lack of sequence similarity to other inhibitors, madanins were classified as a distinct family -family I53 -of the MEROPS database [9] . Madanins display two clusters of acidic residues in the N-terminal two thirds of their amino acid sequence, conferring on them an overall acidic character (theoretical pI of 4.84 and 4.50 for madanin-1 and madanin-2, respectively). Another distinctive feature of madanins is the absence of cysteine residues in their amino acid sequence, placing them in the restricted group of cysteine-less thrombin inhibitors, together with thrombostasin (from the horn fly Haematobia irritans [10] ; MEROPS family I64), tsetse thrombin inhibitor (from Glossina morsitans morsitans [11] ; MEROPS family I76), chimadanin (from H. longicornis [12] ; MEROPS family I72), anophelin (from Anopheles mosquitoes [13] ; MEROPS family I77) and variegin (from the tropical bont tick Amblyomma variegatum [14] ; MEROPS family I74). The molecular mechanism of action of two of these atypical serine proteinase inhibitors, anophelin and variegin, has been unveiled by the crystallographic three-dimensional structures of their complexes with thrombin [15, 16] . Whereas anophelin and variegin bind tightly to thrombin, madanins were shown to bind to thrombin with low affinity [7] . Further, while both variegin and anophelin occupy the active site of the proteinase, albeit with distinct binding modes and mechanisms of inhibition, madanins were proposed to bind only to thrombin's exosite I [7, 17] .
Here we show that inhibitors of MEROPS family I53 are hydrolysed by the blood coagulation factors a-thrombin and factor Xa. In contrast to the also thrombin-cleavable variegin [16] , the inhibitory activity of madanins is lost after the cleavage reaction takes place. In addition to prolonging thrombin time (TT) in a dose-dependent manner, and in contrast to previous reports [7] , we show that madanins inhibit the amidolytic activity of athrombin against a chromogenic substrate and are able to bind to the enzyme's active site. Finally, the crystallographic threedimensional structure of the complex between human a-thrombin and a madanin-1 fragment elucidated the molecular details of madanin-1 recognition and processing by the proteinase.
Materials and Methods
Production of recombinant madanin-1 and madanin-2
Synthetic genes coding for mature Haemaphysalis longicornis madanin-1 and madanin-2, with codon usage optimized for expression in Escherichia coli, were obtained from GenScript. Madanin-1 and madanin-2 ORFs were subcloned into the SapI and PstI restriction sites of the expression vector pTYB11 (New England BioLabs) in fusion with an N-terminal intein tag. E. coli ER2566 cells (New England BioLabs) transformed with pTYB11-madanin-1 or pTYB11-madanin-2 plasmids were grown at 37 uC in lysogeny broth [18] supplemented with 50 mg/ml ampicillin to OD 600 0.5, and expression was induced by addition of isopropyl-b-D-thiogalactopyranoside (0.4 mM final concentration). After overnight growth at 18 uC, cells were lysed by sonication in 20 mM Tris-HCl pH 8.5, 500 mM NaCl, 1 mM ethylenediaminetetraacetic acid (buffer A). Clarified protein extracts were loaded onto chitin-agarose columns (New England BioLabs) preequilibrated with buffer A, and eluted with buffer A supplemented with 50 mM 1,4-dithiothreitol. Protein-containing fractions were concentrated and further purified on a HiPrep 16/60 Sephacryl S-100 column (GE Healthcare) pre-equilibrated with 20 mM TrisHCl pH 8.0, 150 mM NaCl.
Circular dichroism (CD) spectroscopy
Far-UV region (190-260 nm) spectra were recorded in a 1.0 mm path-length quartz cuvette at 20 uC with a Peltier temperature-controlled cell holder-equipped Jasco J-815 spectropolarimeter from a 50 mg/ml protein solution in 20 mM sodium phosphate buffer pH 8.0. Secondary structure content was estimated using the DichroWeb server [19] .
Thrombin time (TT) assays
Human plasma (800 ml) was mixed with 200 ml of recombinant madanin-1 or madanin-2 solution (0, 5 or 10 mM final concentration in 10 mM HEPES pH 7.5, 10 mM NaCl) and thrombin time was measured for each sample at BM Análises Clínicas (http://www.bmac.pt/) using standard protocols.
Thrombin inhibition assays
The inhibition of the amidolytic activity of titrated [20] bovine a-thrombin (GE Healthcare) was followed spectrophotometrically using Tos-Gly-Pro-Arg-p-nitroanilide (Roche) as chromogenic substrate. Assays were performed using 1 nM thrombin and increasing concentrations (0-200 mM) of substrate in the presence of recombinant proteins (0-800 nM). Reactions were carried out at 37 uC in 50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mg/ml bovine serum albumin, and monitored at 405 nm for 1 hour on a Synergy2 multi-mode microplate reader (Biotek). The reactions were started by addition of enzyme. The inhibition constant, K i , was determined by fitting the data to the competitive inhibition model (GraphPad Prism 5), with R 2 parameters of 0.989 (madanin-1) and 0.992 (madanin-2). For each inhibitor, at least three independent experiments with duplicate reactions were performed, together with control reactions in the absence of enzyme.
Madanin fragments were also assayed for their ability to inhibit thrombin. Assays were performed using 1 nM thrombin, 50 mM of chromogenic substrate and 1 mM of fragments or full-length proteins (purified by reverse-phase chromatography as described below). For each inhibitor, triplicate reactions were performed, together with control reactions in the absence of enzyme. Inhibition of thrombin was calculated as percentage of inhibition after 120-min reaction.
Electrophoretic mobility shift assays
Thrombin?madanin complex formation in solution was assessed using non-denaturing PAGE: 30 pmol of human a-thrombin (Haematologic Technologies) were mixed with madanin-1 or madanin-2 (1:1, 1:2, 1:4, 1:8 molar ratios) and incubated at room 
Size exclusion chromatography
Three mg of human a-thrombin (Haematologic Technologies) were mixed with a 10% molar excess of purified madanin-1 and incubated on ice for 1 h. The complex was separated from isolated components by size exclusion chromatography on a Superdex 75 HR10/30 column (GE Healthcare) equilibrated in 50 mM HEPES pH 7.4, 125 mM NaCl. For comparison purposes, thrombin (3 mg) and recombinant madanin-1 (6 mg) were individually applied to the same column.
Cleavage of madanins by thrombin or factor Xa
Madanin-1 or madanin-2 was incubated with human athrombin (Haematologic Technologies) or bovine factor Xa (Roche) at a 10:1 molar ratio. The reactions were quenched after 0 or 2 h incubation at 37uC by addition of 0.1% (v/v) trifluoroacetic acid (TFA, Sigma) before separation by reversephase chromatography.
Reverse-phase chromatography
All reverse-phase chromatography separations were performed at 20 uC using a binary solvent system consisting of 0.1% (v/v) TFA in water (solvent A) and 0.09% (v/v) TFA in gradient-grade acetonitrile (Merck; solvent B). Full-length madanin-1 and its cleavage products were separated on a BioSil 304-10 column (C4-alkyl chains; Bio-Rad) with a linear gradient of 5-55% solvent B in 30 column-volumes and a flow rate of 2 ml/min. Full-length madanin-2 and its cleavage products were separated on a Jupiter 300A C18 column (C18-alkyl chains; Phenomenex) with a linear gradient of 5-45% solvent B in 30 column-volumes and a flow rate of 1 ml/min.
Madanin fragment-containing fractions were pooled and lyophilized. Samples used for TT and thrombin inhibition assays were dissolved in 10 mM HEPES pH 7.5, 10 mM NaCl. Samples used for mass spectrometry (MS) and N-terminal sequencing analysis were dissolved in 20% (v/v) acetonitrile, 0.1% (v/v) TFA.
Protein sequencing and MS analysis
The N-terminal sequence of full-length madanins and madanin fragments were determined by Edman degradation on a Procise 492 protein sequencer (Applied Biosystems). The molecular mass of the peptides was determined by MALDI-TOF on a 4800 Proteomics Analyser (AB Sciex). Samples were crystallized with acyano-4-hydroxycinnamic acid as matrix and analyzed in reflectron mode. Crystallization of the thrombin?madanin-1 complex Thrombin?madanin-1 complex was prepared by mixing human a-thrombin (Haematologic Technologies) with a five-fold molar excess of purified recombinant madanin-1. The complex was concentrated to 19.1 mg/ml on a centrifugal concentration device with a 3 kDa molecular-weight cut-off membrane (Millipore). Crystallization experiments were performed at the EMBL HTX Lab (Grenoble, France) in a Cartesian PixSys 4200 robot (Genomic Solution) using the sitting-drop vapor-diffusion method with commercial sparse-matrix crystallization screens. The experiments were set up in CrystalQuick plates (Greiner) using drops composed of identical volumes (0.1 ml) of protein and precipitant solution, equilibrated against a 88 ml reservoir, and incubated at 20 uC. Crystals were obtained after 7 days using 0.2 M lithium sulfate, 0.1 M Tris-HCl pH 8.5, 25% (w/v) PEG 3350 as precipitant.
Data collection and processing
Crystals were harvested from the CrystalQuick plates, cryoprotected in mother liquor supplemented with 35% PEG 3350, and flash-cooled in liquid nitrogen. Diffraction data from a single cryocooled crystal (100 K) were collected at beamline ID29 [21] of the ESRF (Grenoble) on a Pilatus 6 M detector (Dectris) using a wavelength of 0.9763 Å . One thousand frames were measured in 0.2 u oscillation steps with a 611.6 mm sample-to-detector distance and 0.125 seconds exposure per frame. Diffraction data were integrated with XDS [22] , scaled with XSCALE [23] and reduced with utilities from the CCP4 program suite [24] . Data collection and refinement statistics are summarized in Table 1 .
Structure determination and refinement
The structure of the human a-thrombin?madanin-1 complex was solved by molecular replacement with Phaser [25] using the coordinates of free human a-thrombin as search model (PDB entry 3U69 [26, 27] 
Results and Discussion

Production of recombinant madanins
Madanin-1 and madanin-2 were expressed in E. coli as recombinant proteins and purified by a two-step protocol: affinity chromatography on chitin-agarose followed by size-exclusion chromatography. The integrity of the purified recombinant proteins was verified by mass spectrometry and N-terminal sequencing. The MALDI-MS spectra of purified recombinant madanin-1 and madanin-2 revealed major peaks at 6766.5 Da and 7122.2 Da, respectively, in good agreement with the predicted molecular masses of the full-length forms of the proteins: 6770.2 Da for madanin-1 and 7122.5 Da for madanin-2. Furthermore, both molecules displayed an intact N-terminus, as indicated by the sequence (Tyr-Pro-Glu-Arg) obtained after four cycles of Edman degradation. Finally, circular dichroism spectra of recombinant madanin-1 and madanin-2 are characteristic of ''random-coils'' suggesting that both molecules are intrinsically disordered in solution (Figure 1 ).
Madanins are competitive thrombin inhibitors
In striking contrast to a previous report [7] , we found that under low ionic strength conditions (50 mM NaCl), madanin-1 and madanin-2 compete with a small synthetic chromogenic substrate (Tos-Gly-Pro-Arg-p-nitroanilide) for binding to the active site of thrombin, inhibiting the enzyme in a dose-dependent manner (Figure 2 ). In this experimental setting, madanin-1 and madanin-2 display inhibition constants (K i ) for thrombin of 55.56 6 5.54 nM and 31.62 6 2.53 nM, respectively. Furthermore, both recombinant madanins display anticoagulant activity in vitro, as indicated by the dose-dependent prolongation of thrombin time (TT). Madanin-1 and madanin-2 doubled TT at a concentration of approximately 5 mM (Table 2) , a result that is in agreement with the data previously reported for recombinant madanins containing an additional N-terminal methionine residue [7] .
Madanins are processed by thrombin upon complexation
Complexes between human a-thrombin and madanin-1 or madanin-2 were prepared in vitro and analyzed on an electropho- retic mobility shift assay. A fixed amount of thrombin (30 pmol) was incubated with increasing amounts of purified inhibitor and separated in a non-denaturing gel. When thrombin and madanin-1 or madanin-2 were mixed in equimolar amounts ( Figure 3A and 3B, lane 1) formation of a single species with a slightly different migration profile from thrombin alone ( Figure 3A and 3B, lane 5) was observed, suggesting the formation of a 1:1 thrombin?madanin complex. However, bands migrating faster than free madanin were observed when a molar excess of the inhibitor was used ( Figure 3A and 3B, lanes 2-4) , indicating possible processing of madanins by thrombin. Furthermore, the fast-migrating species observed in non-denaturing gel electrophoresis are protease dosedependent, as demonstrated by electrophoretic mobility shift assays performed with a fixed amount of madanin-1 or madanin-2 (300 pmol) and a range of thrombin concentrations (Figure 4) . The mobility shift between intact madanin and the thrombincleaved inhibitor is significantly larger for madanin-1 than for madanin-2, despite the similar mass, charge, and isoelectric point of both inhibitors (Figure 4) . However, it is conceivable that the differences in the amino acid composition of madanin-1 and madanin-2, albeit small, may originate cleavage fragments with distinct isoelectric points and hence different behavior in the electrophoretic mobility shift assay.
Size-exclusion chromatography analysis of a mixture of athrombin with 10% molar excess of madanin-1 ( Figure 3C , pink) not only shows the formation of a species of higher molecular weight than free thrombin ( Figure 3C, blue) , apparently corresponding to the binary complex, but also the appearance of products ( Figure 3C inset, pink) of lower molecular weight than free madanin-1 ( Figure 3C, grey) . Altogether, these results suggest cleavage of madanins by thrombin at least at one site.
Thrombin cleaves MEROPS family I53 inhibitors
Proteases preferentially cleave substrates within extended loop regions and the cleavage sites are dictated by the specificity of the enzyme [30] . N-terminal sequencing and mass spectrometry analysis of the madanin-1 and madanin-2 hydrolysis products, following separation by reverse-phase HPLC, allowed the identification of the thrombin cleavage sites. Intact madanin-1 and madanin-2 elute from the reverse-phase column as single peaks, having the expected molecular masses in MS analysis ( Figure 5 , Table 3 ). Upon incubation with thrombin, peaks with shorter retention times could be detected, corresponding to inhibitor cleavage products ( Figure 5A, 5C ). For madanin-1, three fragments could be identified: fragment 1, corresponding to madanin-1 residues 1-21; fragment 2, corresponding to residues 22-54; and fragment 3, corresponding to the C-terminal peptide of the inhibitor (residues 55-60; Figure 5A , Table 3 ). For madanin-2, the three major peaks correspond to residues 1-21, 22-55, and 56-61, respectively ( Figure 5C , Table 3 ).
As expected, in all cases a basic amino acid residue could be found at position P1, preceded by a small hydrophobic side chain in P2, in good agreement with thrombin's known substrate specificity [31] (Figure 6 ). Both thrombin cleavage sites are conserved in madanin-like 2, while in madanin-like 1 the residue topologically equivalent to Lys21 of madanin-1 has been replaced by an asparagine (Figure 6 ).
The upstream cleavage site for both madanin-1 (Leu-His-ValLys | Val-Gln-Lys-Arg) and madanin-2 (Leu-Leu-Val-Lys | ValGln-Glu-Arg) resembles the motif found in the physiological substrate protease-activated receptor (PAR)-3 (Leu-Pro-Ile-Lys | Thr-Phe-Arg-Gly) bearing an aliphatic P4 residue (leucine) and a lysine residue at the P1 position. However, thrombin has a strong preference for arginine over lysine at this critical position [31] , and the overwhelming majority of thrombin cleavage sites in natural substrates possess a P1 arginine residue. Therefore, positioning of madanin's Lys21-Val22 peptide bond into the active site of the proteinase in a productive conformation might depend on secondary interactions with one of thrombin's exosites. Indeed, the structure of the thrombin?variegin complex [16] suggests that the hirudin-like motif Asp31-Asp38 in madanin-1 might engage in important contacts with thrombin exosite I residues, similar to the acidic peptides found in variegin [16] and in hirudin [32] [33] [34] , but also in physiological thrombin substrates such as factor V [35] and PAR1 [36] .
Furthermore, the downstream cleavage site for both madanin-1 (Ala-Lys-Pro-Arg | Leu-Arg-Gly-Asn) and madanin-2 (Ala-LysArg-Pro-Arg | Leu-Arg-Gln-Asn) resembles the motif found in the physiological substrates protein C (Val-Asp-Pro-Arg | Leu-IleAsp-Gly), coagulation factors XI (Ile-Lys-Pro-Arg | Ile-Val-GlyGly) and XIII (Val-Val-Pro-Arg | Gly-Val-Asn-Pro), and insulinlike growth factor (Met-Val-Pro-Arg | Ala-Val-Tyr-Leu) [37] . The Table 3 . Thrombin and factor Xa cleave madanin-1 and madanin-2. 
Madanins are also processed by coagulation factor Xa
The proteolytic factor preceding thrombin in the coagulation cascade, factor Xa, has a similar preference for substrates with basic residues at position P1 [38] [39] [40] [41] . Therefore, the ability of factor Xa to hydrolyze madanin-1 and madanin-2 was assessed, following an approach similar to that described above for athrombin. Purification of cleavage products by RP-HPLC, followed by N-terminal sequencing and MS analysis allowed the identification of three factor Xa cleavage sites on each of the inhibitors: Glu-Gln-Glu-Arg | Ala-Leu-His-Val, Val-Gln-Lys-Arg | Thr-Asp-Gly-Asp, and Ala-Lys-Pro-Arg | Leu-Arg-Gly-Asn for madanin-1 and Glu-Lys-Glu-Arg | Ala-Leu-Leu-Val, Val-GlnGlu-Arg | Tyr-Gln-Gly-Asn, and Ala-Arg-Pro-Arg | Leu-ArgGln-Asn for madanin-2 ( Figure 6 ). For madanin-1, two fragments could be identified: fragment 1, corresponding to residues 26-54, and fragment 2, spanning residues 17-54 ( Figure 5B , Table 3 ). For madanin-2, three fragments could be characterized: fragment 1, corresponding to residues 26-55; fragment 2, corresponding to residues 17-25; and fragment 3, corresponding to residues 17-55 ( Figure 5D , Table 3 ).
Thus, factor Xa was found to cleave both madanin-1 and madanin-2 exclusively after arginine residues. The Glu-Gln-GluArg | Ala-Leu-His-Val and Val-Gln-Lys-Arg | Thr-Asp-Gly-Asp cleavage sites in madanin-1 and the topologically equivalent sites in madanin-2 ( Figure 6 ) were recognized as substrate motifs by factor Xa but not by thrombin. This is partially explained by the presence of bulky polar amino acids at position P2 that prevent cleavage by thrombin, with a known strong preference for proline or aliphatic residues at this position [37] . Furthermore, the Cterminal Ala-(Lys/Arg)-Pro-Arg | Leu-Arg-(Gly/Gln)-Asn motif was hydrolyzed by both coagulation factors. The factor Xa cleavage sites are also conserved in madanin-like 1 and madaninlike 2 proteins, with the exception of the most N-terminal site, where the putative P1 residue has been replaced by lysine in madanin-like 2 ( Figure 6 ).
Thrombin-cleaved madanins are devoid of anti-clotting activity
The madanin-1 and madanin-2 fragments resulting from thrombin processing were purified and assayed for anticoagulant activity. Full-length inhibitors subjected to reverse-phase chromatography and lyophilization (Table 4) prolonged thrombin time similarly to unprocessed recombinant proteins (Table 2) . Unlike the full-length polypeptides (Table 4) , the madanin cleavage fragments did not significantly prolong thrombin time, suggesting that the hydrolysis products are unable to compete with thrombin's natural substrate, fibrinogen, for binding to the enzyme. In agreement, the fragments only marginally affected the amidolytic activity of thrombin against a chromogenic substrate in vitro when used at 1000-fold molar excess (Table 5) .
Crystal structure of thrombin in complex with a postcleavage madanin-1 fragment
The three-dimensional structure of human a-thrombin in complex with a cleavage fragment of madanin-1 was determined by X-ray crystallography at a resolution of 2.6 Å . The crystals belong to the orthorhombic space group P2 1 2 1 2 1 and contain two proteinase moieties and a madanin-1 fragment in the asymmetric unit. Each of the two proteinase moieties adopts a structure very similar to that of active ligand-free human thrombin ( [27] , PDB entry 3U69), with a r.m.s.d. of 0.33-0.43 Å (249-251 aligned Ca atoms) for thrombin chains AB and LH, respectively, with most differences being attributable to crystal packing effects. One of the thrombin molecules (chains A and B) is ligand-free, while at the active site of the other proteinase molecule (chains L and H) there is interpretable electron density for madanin-1 residues Ala51 to Arg54 ( Figure 7A ). The ligand-free thrombin molecule packs Table 4 . Thrombin-generated fragments of madanin-1 and madanin-2 do not inhibit plasma clotting. Table 5 . Madanin-1 and madanin-2 hydrolysis products do not inhibit thrombin amidolytic activity.
Thrombin inhibition (%)
No inhibitor 0.00 
